甲胎蛋白对索拉菲尼治疗进展期肝细胞癌的预后评价

近几年来以索拉菲尼为代表的分子靶向药物已成为进展期肝细胞癌综合治疗的热点之一，但目前对于索拉菲尼治疗进展期肝细胞癌的预后评价指标尚没有统一的标准。甲胎蛋白作为重要的肝癌肿瘤标志物，已经广泛地应用于肝细胞癌的筛查诊断，并被认为具有潜在的预测肝细胞癌患者的预后价值。本文总结了近几年来关于甲胎蛋白对索拉菲尼治疗进展期肝细胞癌预后评价的相关文献。从总体上看，甲胎蛋白对于索拉菲尼治疗进展期肝细胞癌预后评价作用是值得肯定的，并可以作为传统的基于影像学资料的肝细胞癌预后评价标准的补充，具有广泛的研究前景和应用价值。

Prognostic evaluation of AFP in advanced hepatocellular carcinoma treated with sorafenib

In recent years，targeted drugs like sorafenib have been the hotspot of comprehensive treatment of advanced hepatocellular carcinoma(HCC).However，there is not comprehensive evaluation indexes for the prognosis of advanced HCC.AFP(Alpha-fetoprotein) has been proved an important marker of HCC.And it is also thought to be possible in predicting prognostic of patients with advanced hepatocellular carcinoma.We summarize the relevant literatures about the prognostic evaluation of AFP in advanced HCC treated with sorafenib in recent years.It should be affirmed that the prognostic evaluation of AFP in advanced HCC treated with sorafenib.AFP can also be used as a supplement for the traditional evaluation criteria of HCC based on imaging studies.The significance of AFP as an predictor for prognosis of HCC treated with sorafenib is considerable in research and clinical application.